STRATEC Biomedical Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/6/2026)
| Balance Sheet | Total Assets | 443,384,000.00 | ROE | 53.52 % |
| Balance Sheet | Total Equity | 237,320,000.00 | ROA | -0.05 % |
| Cashflow | Capital Expenditures | -9,278,000.00 | P/FCF | -30.04 |
| Cashflow | Free Cash Flow | -9,711,000.00 | – | – |
| Cashflow | Operating Cash Flow | -432,999.00 | P/CF | -673.77 |
| Income | Earnings per Share (diluted) | -0.02 | Div. Yield | 2.50 % |
| Income | Net Income | -242,000.00 | P/E | -1,200.00 |
| Income | Shares Outstanding | 12,155,900.00 | P/B | 1.23 |
| Income | Total Revenue | 250,863,000.00 | P/S | 1.16 |
Ratios calculated on: 10/14/2026
Company Description
Stratec Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. As of December 31, 2011 the STRATEC Group operated through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.stratec-biomedical.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more